-
Something wrong with this record ?
Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma
KR. Muthu Raja, L. Rihova, L. Zahradova, M. Klincova, M. Penka, R. Hajek,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12130
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- CD4-Positive T-Lymphocytes drug effects immunology MeSH
- Cyclophosphamide therapeutic use MeSH
- Dexamethasone therapeutic use MeSH
- Adult MeSH
- Hypercalcemia etiology pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Multiple Myeloma complications drug therapy immunology pathology MeSH
- Predictive Value of Tests MeSH
- Disease Progression MeSH
- Proportional Hazards Models MeSH
- Reference Values MeSH
- T-Lymphocytes, Regulatory drug effects immunology pathology MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Case-Control Studies MeSH
- T-Lymphocyte Subsets immunology MeSH
- Thalidomide therapeutic use MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Regulatory T (Treg) cells play an important role in the maintenance of immune system homeostasis. Multiple myeloma (MM) is a plasma cell disorder frequently associated with impaired immune cell numbers and functions. METHODS: We analyzed Treg cells in peripheral blood (n = 207) and bone marrow (n = 202) of pre-malignant and malignant MM patients using flow cytometry. Treg cells and their subsets from MM patients and healthy volunteers were functionally evaluated for their suppressive property. A cohort of 25 patients was analyzed for lymphocytes, CD4 T cells and Treg cells before and after treatment with cyclophosphamide, thalidomide plus dexamethasone (CTD). RESULTS: We found elevated frequencies of Treg cells in newly diagnosed (P<0.01) and relapsed MM patients (P<0.0001) compared to healthy volunteers. Also, Treg subsets including naïve (P = 0.015) and activated (P = 0.036) Treg cells were significantly increased in MM patients compared to healthy volunteers. Functional studies showed that Treg cells and their subsets from both MM and healthy volunteers were similar in their inhibitory function. Significantly increased frequencies of Treg cells were found in MM patients with adverse clinical features such as hypercalcemia (>10 mg/dL), decreased normal plasma cell (≤5%) count and IgA myeloma subtype. We also showed that MM patients with ≥5% of Treg cells had inferior time to progression (TTP) (13 months vs. median not reached; P = 0.013). Furthermore, we demonstrated the prognostic value of Treg cells in prediction of TTP by Cox regression analysis (P = 0.045). CTD treatment significantly reduced frequencies of CD4 T cells (P = 0.001) and Treg cells (P = 0.018) but not Treg cells/CD4 T cells ratio compared to pre-treatment. CONCLUSIONS: Our study showed immune deregulation in MM patients which is evidenced by elevated level of functionally active Treg cells and patients with increased Treg cells have higher risk of progression.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024238
- 003
- CZ-PrNML
- 005
- 20170424094645.0
- 007
- ta
- 008
- 130703s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0047077 $2 doi
- 035 __
- $a (PubMed)23071717
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Muthu Raja, Karthick Raja $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. rajakarthick594@gmail.com $7 _AN046425
- 245 10
- $a Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma / $c KR. Muthu Raja, L. Rihova, L. Zahradova, M. Klincova, M. Penka, R. Hajek,
- 520 9_
- $a BACKGROUND: Regulatory T (Treg) cells play an important role in the maintenance of immune system homeostasis. Multiple myeloma (MM) is a plasma cell disorder frequently associated with impaired immune cell numbers and functions. METHODS: We analyzed Treg cells in peripheral blood (n = 207) and bone marrow (n = 202) of pre-malignant and malignant MM patients using flow cytometry. Treg cells and their subsets from MM patients and healthy volunteers were functionally evaluated for their suppressive property. A cohort of 25 patients was analyzed for lymphocytes, CD4 T cells and Treg cells before and after treatment with cyclophosphamide, thalidomide plus dexamethasone (CTD). RESULTS: We found elevated frequencies of Treg cells in newly diagnosed (P<0.01) and relapsed MM patients (P<0.0001) compared to healthy volunteers. Also, Treg subsets including naïve (P = 0.015) and activated (P = 0.036) Treg cells were significantly increased in MM patients compared to healthy volunteers. Functional studies showed that Treg cells and their subsets from both MM and healthy volunteers were similar in their inhibitory function. Significantly increased frequencies of Treg cells were found in MM patients with adverse clinical features such as hypercalcemia (>10 mg/dL), decreased normal plasma cell (≤5%) count and IgA myeloma subtype. We also showed that MM patients with ≥5% of Treg cells had inferior time to progression (TTP) (13 months vs. median not reached; P = 0.013). Furthermore, we demonstrated the prognostic value of Treg cells in prediction of TTP by Cox regression analysis (P = 0.045). CTD treatment significantly reduced frequencies of CD4 T cells (P = 0.001) and Treg cells (P = 0.018) but not Treg cells/CD4 T cells ratio compared to pre-treatment. CONCLUSIONS: Our study showed immune deregulation in MM patients which is evidenced by elevated level of functionally active Treg cells and patients with increased Treg cells have higher risk of progression.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a CD4-pozitivní T-lymfocyty $x účinky léků $x imunologie $7 D015496
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 _2
- $a dexamethason $x terapeutické užití $7 D003907
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperkalcemie $x etiologie $x patologie $7 D006934
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x komplikace $x farmakoterapie $x imunologie $x patologie $7 D009101
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a referenční hodnoty $7 D012016
- 650 _2
- $a T-lymfocyty - podskupiny $x imunologie $7 D016176
- 650 _2
- $a regulační T-lymfocyty $x účinky léků $x imunologie $x patologie $7 D050378
- 650 _2
- $a thalidomid $x terapeutické užití $7 D013792
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Říhová, Lucie $7 xx0081970
- 700 1_
- $a Szeligová, Lenka $7 xx0098951
- 700 1_
- $a Klincová, Mária $7 _AN050305
- 700 1_
- $a Penka, Miroslav, $d 1952- $7 nlk19990073680
- 700 1_
- $a Hájek, Roman, $d 1964- $7 nlk20000083645
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 7, č. 10 (2012), s. e47077
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23071717 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20170424095001 $b ABA008
- 999 __
- $a ok $b bmc $g 987918 $s 822618
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 7 $c 10 $d e47077 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- GRA __
- $a NT12130 $p MZ0
- LZP __
- $a Pubmed-20130703